Cybin uplisting stock image

(NEO: CYBN) Cybin Granted Conditional Listing Approval by NYSE American

Toronto-based psychedelic drug developer Cybin Inc. announced today that it had received conditional approval to uplist from the NEO Aequitas Exchange to the NYSE American stock exchange. If approved, the company would continue to trade under the ticker CYBN.

Cybin CEO Doug Drysdale commented that, “Conditional listing approval on the NYSE American is an important milestone in Cybin’s growth journey. We expect expanded access to investors to further fuel our mission to develop revolutionary psychedelic therapeutics for patients suffering from mental health conditions.”

The prospective listing remains subject to a pending final approval by the NYSE. 

This development makes Cybin the most recent psychedelics firm to seek a listing on a major exchange. Others include COMPASS Pathways, MindMed, and Field Trip Health. Enveric Biosciences, already Nasdaq-listed, looks to enter the psychedelic arena with it’s planned acquisition of MagicMed Industries currently in progress. 

Cybin was one of the early psychedelic entrants into public markets with an initial listing on the NEO in November of 2020.

The company has previously made news for its target valuations by financial service firms such as Canaccord Genuity and Roth Capital Partners, each of which placed an end-of-year price target on Cybin’s shares of $8 CAD and $10 USD respectively. 

See Also
Natural Mushroom, Psilocybin and Amanita Muscaria

It’s robust pipeline and novel deuterated drug development program have played a large part in these valuations, and in Cybin’s inclusion in major sector ETFs. In a previous interview with Truffle Report, Horizons ETF Management CEO Steve Hawkins described the company as one of two “standouts” — alongside MindMed — in PSYK, the first ever psychedelic industry exchange traded fund.

More recently, Cybin announced it’s collaboration with the University of Washington in clinical trials of psychedelic-assisted therapy with psilocybin to be conducted on front-line clinicians and healthcare workers experiencing depression and distress related to their efforts in combating the ongoing COVID-19 pandemic. These trials are to take place in Seattle.

The author of this piece wishes to disclose that he owns shares of Cybin Inc.

What makes peyote unique among psychedelics?

Lophos Pharma is a #peyote focused psychedelics company co-founded by wife and husband duo Claire and Evan Stawnyczy to explore mescaline’s therapeutic potential.

Read the full interview here: http://ow.ly/kN6w50I3vzt

The push for medical #DMT is on. Truffle Report looks at top corporate and scientific developments involving the spirit molecule from @mindmedco, @AlgernonPharma, @entheonbiomed, @SmallPharma and more.

Full article here: http://ow.ly/khee50HXOHz

#science #business #medicine

Our CEO and Co-Founder @flobrand spoke to @amanda_siebert @Forbes to give deeper context on the significance of our donation to @MAPS and the importance of collaboration between for-profit and non-profits in tackling the #mentalhealth crisis.

See: https://www.forbes.com/sites/amandasiebert/2022/02/16/exclusive-maps-accepts-500k-donation-from-atai-life-sciences-philanthropy-arm/

A Hawaii legislative committee has approved a bill that proposes the establishment of a working group to study the therapeutic benefits of #psilocybin by a vote of 5-0.

Read the full story here: http://ow.ly/4WWI50HWJtL

#psychedelics #healing #medicine #hawaii #legal

"Inspired by a device created by in the 1950s, the creators hope to bring free transcendental experiences to 100,000 Britons – and unite the country through communal hallucinations"

https://www.theguardian.com/artanddesign/2022/feb/16/dreamachine-unboxed-brion-gysin-jon-hopkins-assemble

Load More...

Related Articles

Scroll To Top